Liatis, Stavros
,
Iraklianou, Styliani
Kazakos, Kyriakos
Mastorakos, George
Milios, Kostas
Mouslech, Zadalla
Noutsou, Marina
Pagkalos, Emmanouil
Sampanis, Christos
Funding for this research was provided by:
Sanofi Greece
Article History
Received: 15 February 2018
Accepted: 4 April 2019
First Online: 25 April 2019
Ethics approval and consent to participate
: The study protocol was approved by all Hospitals’ Review Boards and conducted in accordance with Good Pharmacoepidemiology Practices (GCPs) and all applicable regulations. All patients provided written informed consent.
: Not applicable.
: Dr. Stavros Liatis has received research support and/or consulting honoraria from Astra-Zeneca, Boeringer Ingelheim, MSD, Novartis, Novo Nordisk, Sanofi, Pharmaserve Lilly and ELPEN and is a member of the Editorial Board of BMC Endocrine Disorders.Dr. Styliani Iraklianou has received research support and consulting honoraria from Sanofi.Dr. Kyriakos Kazakos has received research support and/or consulting honoraria from Astra Zeneca, Sanofi Aventis, Novo Nordisk and Lilly.Pr. George Mastorakos declares no conflict of interest.Kostas Milios is an employee of Sanofi working as Field Medical for Greece.Dr. Zadalla Mouslech has received research support and/or consulting honoraria from Sanofi and Lilly.Dr. Marina Noutsou has received research support and/or consulting honoraria from Novo Nordisk, Sanofi Aventis, Lilly, Boehringer Ingelheim, ELPEN and Astra Zeneca.Dr. Emmanouil Pagkalos has received research support and/or consulting honoraria from Astra Zeneca, Bayer, ΒΙΑΝΕΧ, Boehringer Ingelheim, ELPEN, Galenica, GSK, Jansen, Lilly, MSD, Novartis, Novo Nordisk, Roche, Sanofi, Takeda and Winmedica.Dr. Christos Sampanis has received research support and /or consulting honoraria from Novo Nordisk, Sanofi and Lilly Co.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.